Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 628

1.

Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.

Norwood P, Liutkus JF, Haber H, Pintilei E, Boardman MK, Trautmann ME.

Clin Ther. 2012 Oct;34(10):2082-90. doi: 10.1016/j.clinthera.2012.09.007.

PMID:
23031623
2.

Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.

Iványi T, Fövényi J, Faludi P, Han J, Macconell L, Wille S, Kiljanski J.

Clin Ther. 2012 Jun;34(6):1301-13. doi: 10.1016/j.clinthera.2012.04.022.

PMID:
22608106
4.

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

Clin Ther. 2008 Aug;30(8):1448-60. doi: 10.1016/j.clinthera.2008.08.006. Erratum in: Clin Ther. 2008 Oct;30(10):1937.

PMID:
18803987
6.

Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.

Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, Hoogwerf BJ, Rosenstock J.

Ann Intern Med. 2011 Jan 18;154(2):103-12. doi: 10.7326/0003-4819-154-2-201101180-00300.

PMID:
21138825
7.

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.

Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, Wilhelm K, Malone J, Porter LE; DURATION-2 Study Group..

Lancet. 2010 Aug 7;376(9739):431-9. doi: 10.1016/S0140-6736(10)60590-9.

PMID:
20580422
9.

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD.

Diabetes Care. 2005 May;28(5):1092-100.

PMID:
15855572
11.

Efficacy and safety of exenatide administered before the two largest daily meals of Latin American patients with type 2 diabetes.

Forti A, Garcia EG, Yu MB, Jimenez MC, Brodows RG, Oliveira JH.

Curr Med Res Opin. 2008 Sep;24(9):2437-47. doi: 10.1185/03007990802282398 .

PMID:
18662495
12.

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.

Wysham C, Bergenstal R, Malloy J, Yan P, Walsh B, Malone J, Taylor K.

Diabet Med. 2011 Jun;28(6):705-14. doi: 10.1111/j.1464-5491.2011.03301.x.

13.

Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.

Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.

Clin Ther. 2007 Nov;29(11):2374-84.

PMID:
18158078
14.

Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.

Pinelli NR, Cha R, Brown MB, Jaber LA.

Ann Pharmacother. 2008 Nov;42(11):1541-51. doi: 10.1345/aph.1L198.

PMID:
18957626
15.

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

Zinman B, Hoogwerf BJ, Durán García S, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG.

Ann Intern Med. 2007 Apr 3;146(7):477-85. Erratum in: Ann Intern Med. 2007 Jun 19;146(12):896.

PMID:
17404349
17.

Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting.

Yoon NM, Cavaghan MK, Brunelle RL, Roach P.

Clin Ther. 2009 Jul;31(7):1511-23. doi: 10.1016/j.clinthera.2009.07.021.

PMID:
19695400
18.

Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.

Bolli G, Dotta F, Colin L, Minic B, Goodman M.

Diabetes Obes Metab. 2009 Jun;11(6):589-95. doi: 10.1111/j.1463-1326.2008.01023.x.

PMID:
19515179
19.

Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.

Bosi E, Dotta F, Jia Y, Goodman M.

Diabetes Obes Metab. 2009 May;11(5):506-15. doi: 10.1111/j.1463-1326.2009.01040.x.

PMID:
19320662
20.

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.

Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L; DURATION-1 Study Group..

Lancet. 2008 Oct 4;372(9645):1240-50. doi: 10.1016/S0140-6736(08)61206-4.

PMID:
18782641
Items per page

Supplemental Content

Support Center